Stock BIOL BIOLASE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus BIOLASE, Inc.

Equities

BIOL

US0909117022

Market Closed - Nasdaq
Other stock markets
 21:00:00 13/05/2024 BST 		5-day change 1st Jan Change
0.1809 USD +7.10% Intraday chart for BIOLASE, Inc. +2.32% -83.88%
10:10pm Earnings Flash (BIOL) BIOLASE Posts Q1 Revenue $10.1M, vs. Street Est of $10M MT
04-01 Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating MT

Evolution of the average Target Price on BIOLASE, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b6780d8d852.inJhUqakIn_UN1M3-Wp0U4HXgLsNhcAUJgtUoAbqgB4.0wIKC-3sF028QzkAiVI6OfC7sNp81YdmFkMO4nWk0i__AzID7d4PFrxCCg~82780b10a53d620ba0f2bda0d529658a

Analyst Recommendations on BIOLASE, Inc.

Ascendiant Capital Adjusts Biolase's Price Target to $4 From $15, Reiterates Buy Rating MT
Wall Street Set to Open Marginally Lower Friday Following Powell Speech, After Hitting Record Highs Thursday MT
Biolase Files Registration Statement for Unit Offering at Target Price of $60 a Unit MT
Lake Street Adjusts Price Target on Biolase to $0.40 From $1.50, Maintains Buy Rating MT
Lake Street Assumes Biolase at Buy With $1.50 Price Target MT
Lake Street Initiates Biolase at Buy, Sets Price Target at $12 MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.1689 USD
Average target price
1.633 USD
Spread / Average Target
+867.04%
High Price Target
4 USD
Spread / Highest target
+2,268.27%
Low Price Target
0.4 USD
Spread / Lowest Target
+136.83%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BIOLASE, Inc.

Ascendiant Capital
Lake Street

Ratings for BIOLASE, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BIOL Stock
  4. Consensus BIOLASE, Inc.